BioNTech SE (BNTX) Return on Capital Employed (2019 - 2025)
BioNTech SE (BNTX) posted Return on Capital Employed of 6.85% for Q4 2025, down 47.77% sequentially from 4.63% in Q3 2025, and down 28.0% YoY from 9.51% in Q4 2024.
BioNTech SE (BNTX) Return on Capital Employed (2019 - 2025) Analysis & Trends
BioNTech SE has reported Return on Capital Employed for 7 years, with the latest figure at 6.85% in Q4 2025.
- Quarterly Return on Capital Employed fell 28.0% year-over-year to 6.85% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 6.85% (down 28.0% YoY) and the FY2025 annual result came in at 7.2%, down 74.0% from the prior year.
- Return on Capital Employed declined to 6.85% in Q4 2025 per BNTX's latest filing, from 4.63% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 171.86% in Q2 2021 and troughed at 6.85% in Q4 2025.
- A 5-year average of 47.21% and a median of 23.11% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2021 and 2023: Return on Capital Employed surged 19264 bps in 2021, then sank 8430 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 93.81% in 2021, then dropped by 7 bps to 87.6% in 2022, then sank by 96 bps to 3.3% in 2023, then plunged by 299 bps to 6.57% in 2024, then declined by 4 bps to 6.85% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 6.85%, 4.63%, and 4.5% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -6.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.85% |
| Sep 30, 2025 | -4.63% |
| Jun 30, 2025 | -4.50% |
| Mar 31, 2025 | -6.64% |
| Dec 31, 2024 | -6.57% |
| Sep 30, 2024 | -4.71% |
| Jun 30, 2024 | -4.41% |
| Mar 31, 2024 | -2.28% |
| Dec 31, 2023 | 3.30% |
| Sep 30, 2023 | 15.88% |
| Jun 30, 2023 | 30.34% |
| Mar 31, 2023 | 55.99% |
| Dec 31, 2022 | 87.60% |
| Sep 30, 2022 | 105.71% |
| Jun 30, 2022 | 119.74% |
| Mar 31, 2022 | 137.26% |
| Dec 31, 2021 | 133.74% |
| Sep 30, 2021 | 155.57% |
| Jun 30, 2021 | 171.86% |
| Mar 31, 2021 | 98.94% |